News & Resources

Overview

Webcast ImageWebcast
Orexigen Therapeutics Conference Call (Replay)
09/11/14 at 8:30 a.m. ET
Orexigen Therapeutics Conference Call
Thursday, September 11, 2014 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is NB32 (naltrexone sustained release (SR) / bupropion SR). Based on successful results of the Light Study, an ongoing cardiovascular outcomes trial, Orexigen's strategy for NB32 is to pursue approvals worldwide and pharmaceutical partnerships for global commercialization. The Company hasMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$5.16
Change (%) Stock is Down 0.12 (2.27%)
Volume7,656,286
Sep 12, 2014 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
DateTitle 
09/11/14Takeda and Orexigen Announce FDA Approval of Contrave® (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management Printer Friendly Version
09/10/14Orexigen Therapeutics to Host Conference Call and Webcast At 8:30 AM Eastern Time September 11, 2014Printer Friendly Version
09/02/14Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. PatentPrinter Friendly Version
08/07/14Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.